Key result
In dogs with left ventricular hypertrophy, maximal activity of soluble myocardial guanylate cyclase was significantly increased to 25.5 pmol/mg protein/min compared to 10.1 in controls, leading to elevated cyclic GMP.
In a canine model of left ventricular hypertrophy, elevated cyclic GMP is driven by increased sensitivity and maximal activity of soluble myocardial guanylate cyclase rather than increased nitric oxide production.
Answers are grounded in this paper and cite their sources.
Animal data implicate upregulated guanylate cyclase in LVH; hypothesis-generating for human cGMP signaling and needs clinical validation.
Left ventricular hypertrophy (LVH) produced by aortic valve plication leads to increased myocardial cyclic GMP. We tested whether this was a result of increased soluble guanylate cyclase activity or nitric oxide (NO) synthase and its functional consequences. We used the nitric oxide donor 3-morpholino-sydnonimine (SIN-1) or the NO synthase inhibitor NG-nitro-l-arginine methyl ester (L-NAME) in 12 control and 12 LVH anesthetized open-chest mongrel dogs. L-NAME (6 mg/kg) or SIN-1 (1 microgram/kg per min) was infused into the left anterior descending coronary artery and regional segment work and cyclic GMP levels were determined. In vitro myocardial guanylate cyclase sensitivity (0.43 +/- 0.04 to 0.28 +/- 0.04 mM [EC50]) and maximal activity (10.1 +/- 2.9 to 25.5 +/- 6.5 pmol/mg protein per min) were significantly increased in LVH as compared with control animals in response to nitroprusside stimulation, but cyclic GMP-phosphodiesterase activity was similar. In LVH dogs, basal cyclic GMP was significantly elevated in vivo when compared with controls. Treatment of dogs with SIN-1 resulted in a significant increase in cyclic GMP in control (1.09 +/- 0.12 to 1.48 +/- 0.19 pmol/gram) and a greater increase in the LVH group (1.78 +/- 0.16 to 3.58 +/- 0.71 pmol/g). L-NAME had no effect on myocardial cyclic GMP levels in control or LVH dogs. Segment work decreased in the control group after SIN-1 (1,573 +/- 290 to 855 +/- 211 grams x mm/min). LVH dogs showed no decrement in work as a result of treatment with SIN-1. L-NAME did not cause significant changes in myocardial cyclic GMP, O2 consumption, or work in either control or LVH dogs, but vascular effects were evident. SIN-1 increased cyclic GMP, and with greater effect on LVH; however, this resulted in a decrement in function only in the control group. The greater increased cyclic GMP in LVH dogs is not related to increased NO production, but is related to significantly higher sensitivity and maximal activity of soluble myocardial guanylate cyclase.
No takes yet. Share an insight, caveat, or question.
Sadoff et al. (1996) studied Left ventricular hypertrophy (n=24). SIN-1 or L-NAME vs. Control dogs and baseline measurements was evaluated on Maximal activity of soluble guanylate cyclase (pmol/mg protein per min) (p=<0.05). In dogs with left ventricular hypertrophy, maximal activity of soluble myocardial guanylate cyclase was significantly increased to 25.5 pmol/mg protein/min compared to 10.1 in controls, leading to elevated cyclic GMP.
Synapse has enriched 10 related papers. Consider them for comparative context: